Kornimate/medical-research-clean huggingface dataset:
feiba to optimize postcardiopulmonary bypass hemostasis in pediatric cardiac patients

Conditions: Cardiac Disease

Summary: the purpose of this research is to understand if the medication called feiba helps to stop bleeding and decrease transfusion of blood products to small children operated on the heart.


Eligibility criteria:
inclusion criteria: * weight ≤ 15 kg. * elective cardiac surgery with cardiopulmonary bypass. * coagulopathic bleeding after cardiopulmonary bypass. * availability and willingness of the parent/legal guardian to provide informed consent. exclusion criteria: * presence of mechanical circulatory support at the time of randomization or pod 0 and 1. * patient or family history of coagulopathy and/or thromboses. * preoperative anticoagulation (excluding low dose heparin for "line prophylaxis").

Keywords: cardiac surgery
effect of electroacupuncture in diabetic patients with gastroparesis

Conditions: Diabetes Mellitus; Gastroparesis

Summary: in this study, we aim at evaluating the effect of electroacupuncture in diabetic patients with gastroparesis. patient-based symptom severity measure, serum parameters and solid-phase gastric emptying time are measured to evaluate the effectiveness of electroacupuncture.

initially, we will collect 30 patients with type 2 diabetes with a ≧ 3-month history of dyspeptic symptoms. an upper gi endocopy will be obtained to rule out possibility of organic obstruction. cardiac arrhythmia and pregnancy will be excluded. none of them ever received abdominal surgery. patients are then randomized to one of two treatment arms. arm i: 15 patients received ea stimulation on acupoints st-36 (zusanli) and li-4 (hegu). arm ii: 15 subjected to ea stimulation on non-acupoints around st-36 and li-4 with the same electrical pulse and amplitude. gastroparesis cardinal symptom index (gcsi) and solid-phase gastric emptying time will be measured on baseline and after ea. in addition, serum gastrin, motilin, human pancreatic polypeptide, fasting blood sugar, and postprandial glucose levels will be also monitored.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * dyspetic symptoms for more than 3 months * symptoms include nausea, vomiting, upper abdominal discomfort, early satiety, bloating and anorexia exclusion criteria: * organic gastrointestinal obstruction * previous surgery of gastrointestinal tract * cardiac arrhythmia * pregnancy

Keywords: diabetes gastroparesis electroacupuncture
inhaled nac in treatment of ipf

Conditions: Idiopathic Pulmonary Fibrosis (IPF)

Summary: this study plans to learn more about the safety and tolerability of inhaled n-acetylcysteine (nac) in patients with pulmonary fibrosis. the study will also create a bank of data, blood, and sputum from ipf patients for future research.

this study plans to learn more about the safety and tolerability of inhaled n-acetylcysteine (nac) in patients with pulmonary fibrosis. the study will also create a bank of data, blood, and sputum from ipf patients for future research. nac is a medication used to loosen thick mucus. nac was initially licensed for use in 1968. it is on the world health organization's list of essential medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. inhaled nac has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production.

Eligibility criteria:
inclusion criteria: * diagnosed by study team with expertise in ipf utilizing standard ats/ers definition of "probable" or "definite" ipf * dlco \>50% predicted * fvc \>60% predicted * fev1/fvc \> 0.7 exclusion criteria: * history of bronchospasm (requiring treatment) * current acute exacerbation of their ipf disease * current smoker * supplemental o2 requirement \> 4 liters/min via nasal cannula * history of asthma, copd, coronary artery disease, or cancer * currently using nac, hypertonic saline, or dnase (dornase alfa) inhalation therapy
safety study of immune system modulator for autoimmune diseases

Conditions: Healthy Volunteers

Summary: the purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of ax-024.hcl in healthy male subjects.


Eligibility criteria:
inclusion criteria: * subjects with a body mass index (bmi) of 18 - 35 kg/m2, inclusive. bmi = body weight (kg) / \[height (m)\]2. * in good health as determined by medical history, physical examination, and clinical judgment of the investigator * subject with no history of autoimmune disease or cardiac disease * subjects must be available to complete the study (including follow-up visit). * subjects must satisfy a medical examiner about their fitness to participate in the study. * subjects must provide written informed consent to participate in the study. exclusion criteria: * a clinically significant history of gastrointestinal disorder likely to influence drug absorption. * receipt of regular medication within 21 days of the first dose that may have an impact on the safety and objectives of the study (at the investigator's discretion). * evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. * subjects who are smokers, or ex-smokers who have smoked in the last 3 months (determined by negative urine cotinine at screening visit). * a clinically significant history of hypersensitivity (anaphylaxis, angioedema) to any drug. * a clinically significant history of drug or alcohol abuse. * participation in a new chemical entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (n.b. washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
improving quality of life after prostate brachytherapy: a comparison of hdr and ldr brachytherapy

Conditions: Prostate Cancer

Summary: optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy. the hypothesis in this randomized study is that a high dose rate (hdr) brachytherapy boost leads to equivalent or better prostate specific antigen (psa) recurrence-free survival when compared to a low dose rate (ldr) brachytherapy boost and that it is associated with a more favorable toxicity profile and improved quality of life.

men with intermediate or high risk prostate cancer who are technically suitable for prostate brachytherapy based on prostate size and voiding function and who are interested in this modality of treatment will be approached for randomization between either high dose rate (single 15 gray) or low dose rate permanent seed implant (110 gray) brachytherapy. baseline international prostate symptom score, quality of life assessment and international index of erectile function will be recorded and then every 3 months for the first year and every 6 months to 3 years. androgen deprivation treatment is allowed for 6 or 12 months.

Eligibility criteria:
inclusion criteria: * upper tier intermediate risk with at least 2 of the following factors 1. tumor-nodes-metastases tumor stage t2b or greater 2. gleason score 7 3. psa \> 10 4. \> 50% of the biopsies positive * or high risk prostate cancer with one of the following factors 1. t3a 2. gleason score8-10 3. psa \>20 * positive prostate biopsy within 6 months (reviewed centrally) * international prostate symptom score \< 16 * prostate volume \< 60 cc * negative staging ct and bone scan within 3 months prior to registration * history and physical examination within 90 days prior to registration * european cooperative oncology group performance status 0-1 prior to registration * age \>45 * patient suitable for procedure under anesthesia exclusion criteria: * prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at least 3 years prior to registration * previous prostatectomy, cryotherapy or high intensity focussed ultrasound for prostate cancer * previous pelvic irradiation or prostate brachytherapy

Keywords: prostatic neoplasm brachytherapy quality of life high dose rate low dose rate
clinician training program to integrate digital cbti into routine psychotherapy

Conditions: Insomnia

Summary: the goal of this study is to pilot test and refine a training program for licensed therapists to promote the integration of digital cognitive behavior therapy for insomnia (dcbti) into their routine mental health care services.


Eligibility criteria:
therapist criteria: inclusion criteria: * licensed mental health clinicians * have a clinical care model that includes seeing patients weekly or biweekly * provide therapy in english * treat patients with depression and/or anxiety * can identify 1-2 patients who are willing to consent to be training cases. exclusion criteria: * not meeting all of the inclusion criteria patient criteria: inclusion criteria: * aged 18+ years old * receive weekly or biweekly therapy from participating study therapist * identify improving sleep as a goal for treatment and experience insomnia (insomnia severity index score greater than or equal to 10) * have daily access to a smartphone, tablet, or computer * can read, write, and speak in english exclusion criteria: * conditions known to make study treatment less effective (e.g., current chronic medication use known to interfere with sleep, alcohol or substance use disorder, thought disorder) * conditions for which dcbti is a safety risk (e.g., bipolar disorder, excessive daytime sleepiness) * current psychotherapy for insomnia
lee011 for patients with cdk4/6 pathway activated tumors (signature)

Conditions: Tumors With CDK4/6 Pathway Activation

Summary: the purpose of this signal seeking study was to determine whether treatment with lee011 demonstrates sufficient efficacy in cdk4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.


Eligibility criteria:
inclusion criteria: * patient had a confirmed diagnosis of a select solid tumor (except breast cancer (however, triple negative was included), liposarcoma, crpc, melanoma and teratoma) or hematological malignancy (except mantle cell lymphoma). * patient must have been pre-identified as having a tumor with cdk4 amplification or mutation, cdk6 amplification or mutation, cyclin d1 (ccnd1) amplification, cyclin d3 (ccnd3) amplification, or p16 (cdkn2a) mutation * patient had received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission. * patient had progressive and measurable disease as per recist 1.1. or other appropriate hematological guidelines. * patient had an eastern cooperative oncology group (ecog) performance status ≤ 1 exclusion criteria: * patients had received prior treatment with lee011. * patient had clinically significant resting bradycardia (heart rate \ 90 at rest), pr interval \> 220 msec, qrs interval \> 109 msec, or qtcf \> 450 msec. * patients had primary cns tumor or cns tumor involvement * patient had received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug

Keywords: solid malignancy hematologic malignancy mutations amplifications signature cdk4 cdk6 cdk4/6 cyclin d1 ccnd, cyclin d3 p16 mutation cdkn2a lee011 breast cancer ovarian cancer lymphoma mesothelioma pancreatic neuroendocrine leukemia tumor
work related msds between egyptian dentists

Conditions: Musculoskeletal Disorder

Summary: the aim of this study is to assess the musculoskeletal pain and discomfort among specialized pediatric dentists and general dentists.

musculoskeletal disorders are caused by the accumulation of mechanical and various stresses on the body, such as repetitive work of specific body parts, uncomfortable and unnatural work postures, high work intensity, excessive force, insufficient rest, cold working environment, and frequency. it is defined as musculoskeletal complaints, musculoskeletal pain that reflect a number of conditions, such as neck pain, back pain, shoulder pain, pain of limbs, carpal tunnel syndrome, myofacial dysfunction syndrome, atypical facial pain although these musculoskeletal disorders can appear in all occupational groups, it is known that the incidence of musculoskeletal pain symptoms is higher in the dentist occupational group than in other occupational groups this is because dentists have to sit or stand for a long time and keep their head, neck, and shoulders in a fixed position for a long time.bending motions, twisting motions, forward bent sitting postures, and relatively static working postures, which dentists mainly take during their treatment, are considered risk factors. according to a study on musculoskeletal disorders in sharkia - low-back pain was the most prevalent musculoskeletal complaint that reported by (56.9%) of the subjects, followed by 50.4%, 47.2% and 42.3% complained of pain in the order of wrist, neck and shoulders valachi and valachi (2003) reported that approximately 81% of us dentists suffered from neck, shoulder and back pain moreover, with the onset of the covid-19 pandemic, the use of additional protective devices increases the mental stress, the risks of imbalanced postures and further reduces the freedom of movement. although there are many studies on musculoskeletal disorders in the dental profession, studies on pediatric dentistry are rare. in the case of pediatric dentists, the cooperation of young patients is insufficient, the treatment time is short, and they are exposed to various environments such as general anaesthesia . in addition, pediatric dental chairs do not fit children of all ages, which affects the attitude of dentists

Eligibility criteria:
inclusion criteria: * graduated egyptian dentists since 2015 , practicing in egypt since 2016 * dentists working hours more than 4 hours and at least 4 days per week * pediatric dentists treating one child at least per working day exclusion criteria: * participants with history of serious trauma or fracture * the presence of serious medical conditions or a transmissible disease such as malignant disease, hepatitis, aids etc. * participants will not sign the consent or complete the questionnaire.
monitoring of biopsy-proven interstitial polyomavirus nephritis in kidney and kidney pancreas transplant recipients

Conditions: Polyomavirus

Summary: evaluate techniques for monitoring the course of interstitial therapy for polyomavirus nephritis in kidney and kidney pancreas transplant recipients by monitoring blood, urine, and renal transplant biopsies of patients affected by polyomavirus.

evaluate techniques for monitoring the course of interstitial therapy for polyomavirus nephritis in kidney and kidney pancreas transplant recipients by monitoring blood, urine, and renal transplant biopsies of patients affected by polyomavirus.

Eligibility criteria:
inclusion criteria: * recipients of a kidney or kidney pancreas transplant diagnosed with biopsy proven interstitial nephritis due to polyomavirus. * age 18 to 70 years. * capable of providing written informed consent. exclusion criteria: * age less than 18 years or greater than 70 years. * patient is on chronic warfarin or heparin therapy or has a disease that puts them at risk of bleeding.

Keywords: monitoring polyomavirus kidney pancreas transplant
cardiac magnetic resonance for diagnosing and guiding treatment in concealed myocardial rupture

Conditions: Early Infarct-associated Pericarditis

Summary: looking for the incidence of concealed myocardial rupture in patients with post infarct pericarditis


Eligibility criteria:
inclusion criteria: * stemi * clinical diagnosis of early infarct-associated pericarditis exclusion criteria: * none
rfa for treatment of intermediate stage hcc

Conditions: Hepatocellular Carcinoma

Summary: in egypt, chronic hepatitis c virus (hcv) is the most prevalent cause of hepatoma. the study aims to evaluate the percutaneous radiofrequency ablation (rfa) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (hcc). the present study was a single-center, prospective non-randomized, controlled clinical trial in the interventional ultrasonography unit, tropical medicine department, beni-suef university hospitals, between october 2018 and august 2021. abdominal ultrasonography and triphasic computerized tomography (ct) abdomen were used to diagnose hcc. the abdominal ultrasonography and a dynamic ct scan were performed six weeks following the ablation to assess treatment efficacy.


Eligibility criteria:
inclusion criteria: * patients were early and intermediate-stage hcc (bclc stage a and b). * patients accepted to be treated by percutaneous radiofrequency ablation in the interventional ultrasonography unit. * patients with early-stage-hcc should have up to 3 tumors, all smaller than 3 cm with a child-pugh a score. * patients with intermediate-stages-hcc should have multinodular hcc (\>3 nodules \<3 cm) or single focal lesion more than 3 cm, with child-pugh score a or b liver cirrhosis, international normalized ratio (inr) less than 1.7, and platelet count more than 50,000/cm. exclusion criteria: * patients with hcc with and vascular spread (portal vein thrombosis), lymph node metastasis or distant metastasis, subcapsular lesions, or lesions with close vicinity to the gall bladder, bowel, or portal vein. * patients with clinically decompensated liver disease (child-pugh score c liver cirrhosis).

Keywords: percutaneous radiofrequency ablation intermediate stage hepatocellular carcinoma clinical trial
cocoa flavanols and painfree walking distance

Conditions: Peripheral Artery Disease; Diabetes Mellitus

Summary: to characterize potential vascular long-term effects of flavanols in patients with peripheral artery occlusive disease (paod), a placebo-controlled double-blinded randomized control study will be performed in 62 patients randomized in two groups. patients will twice daily receive either a flavanol-poor cocoa drink or a flavanol-rich cocoa drink over a period of 60 days months.

62 type 2 diabetics according to the criteria of the american diabetes association suffering from paod with a pain free walking distance less than 250m will be enrolled. patients will twice daily receive either a flavanol-poor cocoa drink (13mg/dl)or a flavanol-rich cocoa drink (596mg/dl) over a period of 60 days. the general condition, the pain free walking distance and the vascular function measured by doppler ultrasound will be determined before and two month after cocoa ingestion

Eligibility criteria:
inclusion criteria: * peripheral artery disease (fontaine iib) * diabetes mellitus * \> 18 years exclusion criteria: * acute and terminal renal failure * acute infection * heart failure (nyha iii-iv) * arrhythmias
st segment resolution after primary percutaneous coronary intervention.

Conditions: ST Segment Elevation Myocardial Infarction

Summary: to compare the st segment resolution after primary percutaneous coronary intervention (ppci) with and without thrombus aspiration in patients with st segment elevation myocardial infarction as st segment resolution is the best indicator for the prediction of the outcome and mace

the idea of an occluding thrombus and its dissolution had been stated since the 1950s.1 thrombus is present in the infarct-related artery in 88% of patients undergoing coronary artery angiography within the first 4 h of acute myocardial infarction (ami). the finding of st segment elevation in a patient presenting with chest pain allows rapid identification of those who benefit from emergency reperfusion. primary percutaneous coronary intervention (ppci) is now the preferred strategy for emergency reperfusion in patients presenting with st elevation myocardial infarction (stemi). thrombus aspiration (ta) might be an effective procedure for reducing distal embolization and improving microvascular perfusion in st-segment elevation myocardial infarction (stemi), especially in patients with high thrombus burden. despite the class iii recommendation for routine thrombus aspiration use before balloon angioplasty or stenting. manual thrombus aspiration might still remain a useful strategy for the interventional cardiologist when treating selected patients with significant thrombus burden during ppci. thrombus grading is classified as: grade 0: no angiographic characteristics of thrombus are present. grade 1: possible thrombus is present with a such characteristics as: reduced contrast density, haziness, irregular lesion contour or smooth convex meniscus at the site of total occlusion suggestive but not diagnostic of the thrombus. grade 2: there is a definite thrombus with greatest dimension \<1/2 the vessel diameter. grade 3: there is a definite thrombus but with greatest linear dimension\>1/2 but \<2 vessel dimension. grade 4: there is a definite thrombus but with greatest linear dimension \>2 vessel dimension. grade 5: there is a total occlusion (unable to assess thrombus burden due to total vessel occlusion. the analysis of st-segment resolution on the electrocardiogram (ecg) consists of a simple tool, of easy use and low cost, able to document success of the epicardial reperfusion and tissue reperfusion after primary pci. the persistence of st-segment elevation on the ecg, despite the restoration of a normal epicardial flow, signifies a poor prognosis; such persistence is known to be associated with larger infarct size and higher combined rate of severe cardiovascular adverse events.

Eligibility criteria:
inclusion criteria: . patients with stemi within 24 hours of chest pain.patients killip class 1 is included in this study xclusion criteria: * killip ii-iv * previous myocardial infarction * patients with left bundle branch block * patients with advanced cancer disease * patients qith contraindications to anti-coagulation * patients with sensitivity to clopidogrel